About Neurocrine UK
Neurocrine UK is a company based in Cardiff (United Kingdom) founded in 2004 was acquired by Neurocrine in August 2022. It operates as a HealthTech. Neurocrine UK has raised $10.1 million across 5 funding rounds from investors including Pfizer, Neurocrine and IP Group. The company has 36 employees as of June 30, 2021. Neurocrine UK offers products and services including Healthcare Solutions. Neurocrine UK operates in a competitive market with competitors including Crinetics, Zucara Therapeutics, MBX Biosciences, Neurocrine and Amolyt Pharma, among others.
- Headquarter Cardiff, United Kingdom
- Employees 36 as on 30 Jun, 2021
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neurocrine Uk Ltd
-
Annual Revenue
$5.89 M (USD)-31as on Jun 30, 2021
-
Net Profit
$-13.53 M (USD)-147as on Jun 30, 2021
-
EBITDA
-
Total Equity Funding
$10.1 M (USD)
in 5 rounds
-
Latest Funding Round
$10.43 M (USD), Post-IPO
Oct 09, 2020
-
Investors
Pfizer
& 2 more
-
Employee Count
36
as on Jun 30, 2021
-
Acquired by
Neurocrine
(Aug 30, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Neurocrine UK
Neurocrine UK offers a comprehensive portfolio of products and services, including Healthcare Solutions. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Solutions are provided to address significant healthcare needs.
Funding Insights of Neurocrine UK
Neurocrine UK has successfully raised a total of $10.1M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10.43 million completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Post-IPO — $10.4M
-
First Round
First Round
(30 Apr 2009)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2020 | Amount | Post-IPO - Neurocrine UK | Valuation |
investors |
|
| Mar, 2020 | Amount | Post-IPO - Neurocrine UK | Valuation |
investors |
|
| Feb, 2018 | Amount | Post-IPO - Neurocrine UK | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neurocrine UK
Neurocrine UK has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Pfizer, Neurocrine and IP Group. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and advisory services are offered across multiple sectors.
|
Founded Year | Domain | Location | |
|
Pharmaceutical products for treating multiple diseases are provided.
|
Founded Year | Domain | Location | |
|
Developer of small molecule therapeutics for endocrine and CNS disorders
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neurocrine UK
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Neurocrine UK
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurocrine Uk Comparisons
Competitors of Neurocrine UK
Neurocrine UK operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Crinetics, Zucara Therapeutics, MBX Biosciences, Neurocrine and Amolyt Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neurocrine Uk
Frequently Asked Questions about Neurocrine UK
When was Neurocrine UK founded?
Neurocrine UK was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Where is Neurocrine UK located?
Neurocrine UK is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
Who is the current CEO of Neurocrine UK?
Richard Bungay is the current CEO of Neurocrine UK.
Is Neurocrine UK a funded company?
Neurocrine UK is a funded company, having raised a total of $10.1M across 5 funding rounds to date. The company's 1st funding round was a Post-IPO of $15.32M, raised on Apr 30, 2009.
How many employees does Neurocrine UK have?
As of Jun 30, 2021, the latest employee count at Neurocrine UK is 36.
What is the annual revenue of Neurocrine UK?
Annual revenue of Neurocrine UK is $5.89M as on Jun 30, 2021.
What does Neurocrine UK do?
Neurocrine UK is dedicated to addressing significant healthcare needs by providing solutions aimed at relieving suffering. The company operates within the biotechnology sector, focusing on neurological treatments and related areas. Based in Cardiff, UK, it serves both UK and non-UK residents with its offerings. The organization is committed to improving patient outcomes through innovative approaches in the healthcare industry.
Who are the top competitors of Neurocrine UK?
Neurocrine UK's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
What products or services does Neurocrine UK offer?
Neurocrine UK offers Healthcare Solutions.
Who are Neurocrine UK's investors?
Neurocrine UK has 3 investors. Key investors include Pfizer, Neurocrine, and IP Group.